A5046642925- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease and Transplantation
- Gallbladder and Bile Duct Disorders
- Congenital Anomalies and Fetal Surgery
- Hepatitis Viruses Studies and Epidemiology
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Intestinal Malrotation and Obstruction Disorders
- Clinical Nutrition and Gastroenterology
- Metabolism and Genetic Disorders
- Neonatal Health and Biochemistry
- Viral gastroenteritis research and epidemiology
- Drug Transport and Resistance Mechanisms
- Esophageal and GI Pathology
- Drug-Induced Hepatotoxicity and Protection
- Infant Nutrition and Health
- Chronic Lymphocytic Leukemia Research
- Cystic Fibrosis Research Advances
- Adolescent and Pediatric Healthcare
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Child Nutrition and Feeding Issues
Johns Hopkins Medicine
2016-2025
Johns Hopkins University
2016-2025
Rady Children's Hospital-San Diego
2022-2024
University of California, San Diego
2020-2023
Research Network (United States)
2022
Institut für Sozialforschung und Sozialwirtschaft
2022
Johns Hopkins Hospital
1995-2021
Arbor Research Collaborative for Health
2021
University of California, San Francisco
2021
Children's Hospital of Philadelphia
2019
No all-oral, direct-acting antiviral regimens have been approved for children with chronic hepatitis C virus (HCV) infection. We conducted a phase 2, multicenter, open-label study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents HCV genotype 1 One hundred patients aged 12-17 years received combination tablet 90 mg ledipasvir 400 sofosbuvir once daily 12 weeks. On tenth day following initiation dosing, 10 underwent an intensive pharmacokinetic evaluation...
The epidemiology of primary hepatic malignancies in U.S. children is poorly characterized. We analyzed the incidence, mortality, and characteristics residents less than 20 years age. Fatal persons age, between 1979 1996, were identified using multiple-cause-of-death database (National Center for Health Statistics). Histologically confirmed occurring 1973 1997 Surveillance, Epidemiology, End Results (SEER) database. Between 918 malignancy deaths (average, 0.7/1,000,000/year) reported...
Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment with virus (HBV) children.
There is relatively little information in the literature on histopathology of chronic hepatitis C children. The Peds-C Trial, designed to test efficacy and safety peginterferon alfa-2a ribavirin children, provided an opportunity examine liver biopsies from 121 treatment-naïve ages 2 16 (mean, 9.8 years) infected with virus (HCV) no other identifiable cause for disease, signs hepatic decompensation, or another significant nonhepatic disease. Liver were scored inflammation, fibrosis,...
ABSTRACT Hepatitis C virus (HCV) is an RNA that affects >180 million individuals worldwide with a high propensity for chronic infection. Children HCV infection differ from adults in several ways including some modes of transmission, rates clearance, progression fibrosis, and the duration potential when acquired at birth. Since discovery 1989, there have been significant advances understanding virology natural history children. In addition, are now treatment options children hepatitis many...
Biliary atresia is the most common cause of end-stage liver disease in children. Controversy exists as to whether use steroids after hepatoportoenterostomy improves clinical outcome.
Late graft loss (LGL) and late mortality (LM) following liver transplantation (LT) in children were analyzed from the studies of pediatric (SPLIT) database. Univariate multivariate associations between pre‐ postoperative factors LGL LM 872 patients alive with their primary allografts 1 year after LT reviewed. Thirty‐four subsequently died 35 underwent re‐LT (LGL). Patients who survive first posttransplant had 5‐year patient survival rates 94.2% 89.2%, respectively. Graft was caused by...
N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE). Because non-APAP ALF differs significantly between children adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC PALF. Children from birth through age 17 years enrolled PALF registry were eligible enter an adaptively allocated, doubly masked, placebo-controlled trial using a...
Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing and choice antiviral therapy are complex compounded by limited number drugs that have been studied children. An expert panel nationally recognized pediatric liver specialists was convened Hepatitis Foundation on August 11, 2009, to consider clinical practice relative options available A...
The etiology of biliary atresia (BA) is unknown. Given that patterns anomalies might provide etiopathogenetic clues, we used data from the North American Childhood Liver Disease Research and Education Network to analyze in infants with BA. In all, 289 who were enrolled prospective database prior surgery at any 15 participating centers evaluated. Group 1 was nonsyndromic, isolated BA (without major malformations) (n = 242, 84%), 2 least one malformation considered as defined by National Birth...
Children with chronic hepatitis C virus infection have limited treatment options. We evaluated the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 genotype 2 or 3 (ClinicalTrials.gov NCT02175758). Fifty-two patients received 400 mg once daily weight-based twice for 12 (genotype 2) 24 3) weeks. The pharmacokinetics its metabolite GS-331007 were by intensive plasma sampling at day 7 first 10 enrolled sparse all throughout treatment. primary efficacy endpoint was...
Currently, there are no interferon-free treatments available for hepatitis C virus (HCV)-infected patients younger than 12 years. We evaluated the safety and effectiveness of all-oral regimen ledipasvir-sofosbuvir ± ribavirin in HCV-infected children aged 6 to <12 In an open-label study, years received ledipasvir 45 mg-sofosbuvir 200 mg as two fixed-dose combination tablets 22.5/100 once daily, with or without ribavirin, 24 weeks, depending on HCV genotype cirrhosis status. The primary...
For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct-acting antiviral agents. We therefore evaluated the safety and efficacy ledipasvir-sofosbuvir in HCV-infected aged 3 to <6 years. In an open-label study, patients old chronically infected HCV genotype 1 (n = 33) or 4 1) received weight-based doses combined as granules (33.75 mg/150 mg for weights <17 kg 45 mg/200 ≥17 kg) weeks. The primary endpoint was...
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, real‐world lacking. This study aimed to elucidate the natural history of liver disease in contemporary, international cohort children with ALGS. Approach Results: was multicenter retrospective clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 August 2019. Native survival (NLS) event‐free rates...
Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine effect of IBD activity. Methods In this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based duration at time outcome assessment. The was Physician Global Assessment (PGA) clinical activity after 1 year (±6 months) vancomycin. We used...
One year of lamivudine treatment results in increased hepatitis B e antigen (HBeAg) seroconversion and serum virus (HBV) DNA negativity children with chronic high alanine aminotransferase concentrations. Two hundred seventy-six who participated a 1-year randomized, placebo-controlled study were enrolled 24-month, open-label extension. Patients stratified into two groups based on HBeAg status at week 48 the previous study: 213 HBeAg-positive entered arm, 63 HBeAg-negative an observation arm...
Hepatitis C virus (HCV) infection is a global health problem affecting 170 million individuals worldwide. In the United States, there are approximately 7 adults and 100,000 children chronically infected with HCV (1,2). The importance of stems from its proclivity to cause insidious liver damage over many years, including chronic hepatitis, cirrhosis, cancer. adults, leading for cancer worldwide (3). financial burden this viral staggering, projected medical costs $10.7 billion in 2010 2019...
ABSTRACT Objective: Hepatitis C virus (HCV) infection is associated with decreased quality of life (QOL) and neurocognitive dysfunction in adults, but little known about its impact on children their caregivers. Patients Methods: We studied the QOL, behavioral, emotional, cognitive functioning 114 treatment‐naïve HCV enrolled a placebo‐controlled, randomized, multisite clinical trial evaluating peginterferon α‐2a alone or ribavirin. Baseline assessment included measures children's...
Malnutrition is a significant clinical problem in infants with biliary atresia. The natural history of poor growth and its potential association early transplantation or death children atresia was determined. Serial weight- length-for-age z-scores were computed as part retrospective study 100 who underwent hepatoportoenterostomy (HPE) for at 9 U.S. pediatric centers between 1997 2000. Poor outcome defined by 24 months age (n = 46) good survival native liver total serum bilirubin less than 6...